What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Investor's Business Daily on MSN2h
Amgen Crashes 9% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Becker's Hospital Review2h
6 GLP-1 study findings to know
Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...
S&P 500 Gains and Losses Today: NRG Energy Stock Surges After Analyst Upgrade
The S&P 500 added 0.6% on Tuesday, Nov. 26, as investors weighed the implications of President-elect Donald Trump's promise ...
Novo, Lilly shares rise as Biden proposes obesity care coverage
Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...
Amgen's weight-loss drug fails to impress in study; shares plunge
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
MedPage Today5h
Thyroid Drug & Bone Loss; GLP-1s' Renal Benefit; Menopause Musculoskeletal Syndrome
The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...
Amgen: MariTide Underwhelms, But There Are Ways To Win
Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Reuters on MSN5h
Amgen shares fall on anti-obesity drug; rivals Novo and Lilly gain
Share of Amgen tumbled on Tuesday after the company's experimental weight-loss drug MariTide failed to meet lofty investor ...
Amgen’s MariTide only differentiation seems to be dosing frequency, says Leerink
Leerink notes that Amgen’s Phase 2 MariTide showed “up to ~20% average weight loss at 52 weeks” in nondiabetic obese/overweight patients, which is roughly on par with the hi ...